For patients with locally advanced gastric cancer(LAGC),the effectiveness of perioperative chemotherapy can be significantly improved by adding programmed cell death protein 1(PD-1)inhibitors during the neoadjuvant ph...For patients with locally advanced gastric cancer(LAGC),the effectiveness of perioperative chemotherapy can be significantly improved by adding programmed cell death protein 1(PD-1)inhibitors during the neoadjuvant phase.However,a substantial percentage of patients with a programmed death-ligand 1 combined positive score(PD-L1 CPS)<1 or microsatellite stable(MSS)status may still not experience benefits.展开更多
基金supported by Jiangsu Hengrui Medicine Co.,Ltd.&Innovent Biologics(Suzhou)Co.,Ltd,the Fundamental Research Funds for the Central Universities of Lanzhou University(Nos.lzujbky-2022-ey04 and lzujbky-2023-eyt04)the Science and Technology Program of Gansu Province,China(Nos.21JR1RA144 and 22JR5RA961)the Cuiying Scientific and Technological Innovation Program of Lanzhou University Second Hospital,China(Nos.CY2020-MS10 and CY2023-QN-A02).
文摘For patients with locally advanced gastric cancer(LAGC),the effectiveness of perioperative chemotherapy can be significantly improved by adding programmed cell death protein 1(PD-1)inhibitors during the neoadjuvant phase.However,a substantial percentage of patients with a programmed death-ligand 1 combined positive score(PD-L1 CPS)<1 or microsatellite stable(MSS)status may still not experience benefits.
